184 related articles for article (PubMed ID: 30353046)
21. Osteopontin splice variants and polymorphisms in cancer progression and prognosis.
Briones-Orta MA; Avendaño-Vázquez SE; Aparicio-Bautista DI; Coombes JD; Weber GF; Syn WK
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):93-108.A. PubMed ID: 28254527
[TBL] [Abstract][Full Text] [Related]
22. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
[TBL] [Abstract][Full Text] [Related]
23. Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR.
Reinholz MM; Iturria SJ; Ingle JN; Roche PC
Breast Cancer Res Treat; 2002 Jun; 74(3):255-69. PubMed ID: 12206515
[TBL] [Abstract][Full Text] [Related]
24. Crossroads: the role of biomarkers in the management of lumps in the breast.
Weber GF
Oncotarget; 2023 Apr; 14():358-362. PubMed ID: 37096988
[TBL] [Abstract][Full Text] [Related]
25. Overexpressed ostepontin-c as a potential biomarker for esophageal squamous cell carcinoma.
Zhang MX; Xu YJ; Zhu MC; Yan F
Asian Pac J Cancer Prev; 2013; 14(12):7315-9. PubMed ID: 24460294
[TBL] [Abstract][Full Text] [Related]
26. Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype.
Li NY; Weber CE; Mi Z; Wai PY; Cuevas BD; Kuo PC
J Am Coll Surg; 2013 Jul; 217(1):17-26; discussion 26. PubMed ID: 23619316
[TBL] [Abstract][Full Text] [Related]
27. The osteopontin-c splice junction is important for anchorage-independent growth.
Shen H; Weber GF
Mol Carcinog; 2014 Jun; 53(6):480-7. PubMed ID: 23359517
[TBL] [Abstract][Full Text] [Related]
28. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas.
Tuck AB; O'Malley FP; Singhal H; Tonkin KS; Harris JF; Bautista D; Chambers AF
Arch Pathol Lab Med; 1997 Jun; 121(6):578-84. PubMed ID: 9199622
[TBL] [Abstract][Full Text] [Related]
29. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
[TBL] [Abstract][Full Text] [Related]
30. Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer.
Rohde F; Rimkus C; Friederichs J; Rosenberg R; Marthen C; Doll D; Holzmann B; Siewert JR; Janssen KP
Int J Cancer; 2007 Oct; 121(8):1717-23. PubMed ID: 17565744
[TBL] [Abstract][Full Text] [Related]
31. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions.
Weinstat-Saslow D; Merino MJ; Manrow RE; Lawrence JA; Bluth RF; Wittenbel KD; Simpson JF; Page DL; Steeg PS
Nat Med; 1995 Dec; 1(12):1257-60. PubMed ID: 7489405
[TBL] [Abstract][Full Text] [Related]
33. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers.
Collins LC; Carlo VP; Hwang H; Barry TS; Gown AM; Schnitt SJ
Am J Surg Pathol; 2006 Aug; 30(8):1002-7. PubMed ID: 16861972
[TBL] [Abstract][Full Text] [Related]
34. A useful immunohistochemical approach to evaluate intraductal proliferative lesions of the breast and to predict their prognosis.
Omi Y; Yamamoto T; Okamoto T; Obara T; Kobayashi M
Histol Histopathol; 2011 Jan; 26(1):79-86. PubMed ID: 21117029
[TBL] [Abstract][Full Text] [Related]
35. Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity.
Devoll RE; Li W; Woods KV; Pinero GJ; Butler WT; Farach-Carson MC; Happonen RP
J Oral Pathol Med; 1999 Mar; 28(3):97-101. PubMed ID: 10069535
[TBL] [Abstract][Full Text] [Related]
36. Expression of osteopontin and CDX2: indications of phenotypes and prognosis in advanced gastric cancer.
Zhang X; Tsukamoto T; Mizoshita T; Ban H; Suzuki H; Toyoda T; Tatematsu M
Oncol Rep; 2009 Mar; 21(3):609-13. PubMed ID: 19212618
[TBL] [Abstract][Full Text] [Related]
37. The role of osteopontin expression in melanoma progression.
Kiss T; Ecsedi S; Vizkeleti L; Koroknai V; Emri G; Kovács N; Adany R; Balazs M
Tumour Biol; 2015 Sep; 36(10):7841-7. PubMed ID: 25944164
[TBL] [Abstract][Full Text] [Related]
38. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival.
Wu CY; Wu MS; Chiang EP; Wu CC; Chen YJ; Chen CJ; Chi NH; Chen GH; Lin JT
Gut; 2007 Jun; 56(6):782-9. PubMed ID: 17148500
[TBL] [Abstract][Full Text] [Related]
39. Progression risk of columnar cell lesions of the breast diagnosed in core needle biopsies.
Verschuur-Maes AH; Witkamp AJ; de Bruin PC; van der Wall E; van Diest PJ
Int J Cancer; 2011 Dec; 129(11):2674-80. PubMed ID: 21225627
[TBL] [Abstract][Full Text] [Related]
40. Conditional Knockdown of Osteopontin Inhibits Breast Cancer Skeletal Metastasis.
Kovacheva M; Zepp M; Schraad M; Berger S; Berger MR
Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31590218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
